AI Article Synopsis
- Extramammary Paget disease (EMPD) is a rare skin cancer mainly affecting older adults in the anogenital areas, with no proven treatments from clinical trials so far.
- Researchers created a patient-derived xenograft model to test various treatments, discovering that eribulin showed significant effectiveness against EMPD tumors.
- A phase II clinical trial, started in October 2022, is assessing eribulin's efficacy in unresectable EMPD patients, with plans to establish it as a standard treatment if results are positive.
Article Abstract
Extramammary Paget disease (EMPD) is a rare cutaneous malignancy that predominantly affects the anogenital areas of the elderly. Although the efficacy of docetaxel and other cytotoxic agents for advanced EMPD has been reported in small retrospective case studies, no treatment has been proven effective in prospective clinical trials. We established the world's first in vivo EMPD experimental model (a patient-derived xenograft model). In our treatment experiment, xenograft tumours showed a remarkable response to eribulin. This study evaluates the efficacy of eribulin for patients with advanced EMPD. In October 2022, we started a single-arm phase II trial to evaluate the efficacy of eribulin as a treatment for adult patients with unresectable EMPD with measurable lesions. Enrolment in this clinical trial is open to patients with any prior treatment for EMPD. The primary endpoint is overall response rate; the secondary endpoints include disease control rate, overall survival, progression-free survival and adverse events. The study protocol was approved by the Ethics Committee of Hokkaido University and the other collaborating institutions. If the primary endpoint is met, it is our hope that eribulin will be regarded as a standard medication for patients with advanced EMPD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/exd.14993 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pembrolizumab has been found effective against various solid tumors with high tumor mutation burden, but there are no reports of successful treatment with pembrolizumab for extramammary Paget's disease (EMPD) with a high tumor mutation burden (TMB). This report describes a 71-year-old male patient who presented with irregularly shaped erythematous lesions on his scrotum, which had been there for several years. He was diagnosed with EMPD.
View Article and Find Full Text PDFTislelizumab plus chemotherapy in metastatic extramammary Paget disease after surgery: a case report.
Front Oncol
October 2024
Department of Urology, The 940t Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou, Gansu, China.
Article Synopsis
- Extramammary Paget disease (EMPD) is a rare type of skin cancer that mainly affects areas with apocrine glands like the vulva, scrotum, and penis, and often has a poor prognosis, especially with distant metastases.
- Patients with localized EMPD generally have a good 5-year survival rate between 60%-92%, while those with metastases only have about a 10% survival rate.
- A case report highlights a 57-year-old man with metastatic EMPD who responded well to a combination of an immune checkpoint inhibitor and chemotherapy, suggesting this approach may improve outcomes for others with similar advanced disease.*
Extramammary Paget's disease treated with of anti-programmed cell death protein 1 therapy after docetaxel therapy failure.
J Dermatol
October 2024
Department of Dermatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
Extramammary Paget's disease (EMPD) is a rare skin cancer with no standard treatment for advanced-stage disease. Although docetaxel-based chemotherapy is common, no standard treatment exists. Pembrolizumab is approved for solid tumors with a high tumor mutation burden (TMB) and/or high microsatellite instability, and nivolumab was approved in Japan in February 2024 for unresectable advanced or recurrent epithelial skin malignancies.
View Article and Find Full Text PDFAssociation of genetic alterations with prognosis in extramammary Paget disease: insights into the involvement of somatic CDKN2A variants in patients with a poor prognosis.
Br J Dermatol
December 2024
Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Article Synopsis
- Previous studies have noted the mutational landscape of extramammary Paget's disease (EMPD), but the impact of genetic alterations on prognosis, especially CDKN2A loss, was not previously explored.* -
- In a retrospective study involving 167 registered EMPD cases, researchers found that CDKN2A loss was the most common variant, and both CDKN2A and BRCA2 mutations were linked to worse patient outcomes.* -
- Patients with CDKN2A mutations had a significantly poorer prognosis compared to those without, and those with BRCA2 mutations also fared worse, indicating the importance of genetic profiling in understanding EMPD prognosis.*
The Role of Line-Field Confocal Optical Coherence Tomography in Detecting Extramammary Paget Disease Recurrences: A Pilot Diagnostic Study.
Diagnostics (Basel)
July 2024
Department of Dermatology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), HUB, 1070 Brussels, Belgium.
Article Synopsis
- Extramammary Paget disease (EMPD) is a rare skin cancer that often gets misdiagnosed due to its misleading appearance, complicating effective treatment and diagnosis.
- Traditional methods like biopsies are invasive and can be uncomfortable for patients, and non-invasive techniques have limited effectiveness.
- Line-field confocal optical coherence tomography (LC-OCT) is a promising new imaging technology that provides better diagnostic accuracy for EMPD and its recurrence, with a study showing much higher accuracy rates after proper training in its use.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!